These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 38905267)

  • 1. The efficacy and safety of different Janus kinase inhibitors as monotherapy in rheumatoid arthritis: A Bayesian network meta-analysis.
    Qu B; Zhao F; Song Y; Zhao J; Yao Y; Chen Y; Liao R; Fu L
    PLoS One; 2024; 19(6):e0305621. PubMed ID: 38905267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
    Ho Lee Y; Gyu Song G
    J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with janus kinase inhibitors: A systematic review and meta-analysis.
    Ouranos K; Avila DV; Mylona EK; Vassilopoulos A; Vassilopoulos S; Shehadeh F; Mylonakis E
    PLoS One; 2024; 19(7):e0306548. PubMed ID: 39083492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis.
    Lee YH; Song GG
    Z Rheumatol; 2020 Oct; 79(8):785-796. PubMed ID: 32055928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
    Song GG; Choi SJ; Lee YH
    Int J Rheum Dis; 2019 Aug; 22(8):1563-1571. PubMed ID: 31211506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy of new JAK inhibitors under development. Just more of the same?
    Westhovens R
    Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i27-i33. PubMed ID: 30806706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs.
    Lee YH; Song GG
    Z Rheumatol; 2021 May; 80(4):379-392. PubMed ID: 32367211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-naïve patients with rheumatoid arthritis.
    Sung YK; Lee YH
    Z Rheumatol; 2021 Nov; 80(9):889-898. PubMed ID: 32970188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the efficacy and safety of tofacitinib and filgotinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Song GG
    Z Rheumatol; 2020 Aug; 79(6):590-603. PubMed ID: 31781849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
    Pope J; Sawant R; Tundia N; Du EX; Qi CZ; Song Y; Tang P; Betts KA
    Adv Ther; 2020 May; 37(5):2356-2372. PubMed ID: 32297280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse reactions to Janus kinase inhibitors: Study of their incidence and predictive factors in patients with rheumatoid arthritis.
    Martinez-Molina C; Guardiola Tey JM; Ruiz-Ramos J; Feliu A; Puig-Campmany M; Vidal S; Corominas H
    Med Clin (Barc); 2024 Oct; 163(8):391-396. PubMed ID: 39003114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - A network meta-analysis.
    Zhang L; Guo L; Wang L; Jiang X
    J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):1937-1946. PubMed ID: 35608188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world comparative study of drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis.
    Saito K; Yoshida S; Ebina H; Miyata M; Suzuki E; Kanno T; Sumichika Y; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Asano T; Sato S; Migita K
    PLoS One; 2024; 19(7):e0306714. PubMed ID: 38990897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
    Wang F; Sun L; Wang S; Davis JM; Matteson EL; Murad MH; Luo F; Vassallo R
    Mayo Clin Proc; 2020 Jul; 95(7):1404-1419. PubMed ID: 32499126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
    Bae SC; Lee YH
    Z Rheumatol; 2019 Aug; 78(6):559-567. PubMed ID: 30191390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative remission rates of Janus kinase inhibitors in comparison with adalimumab in patients with active rheumatoid arthritis: a network meta-analysis.
    Lee YH; Song GG
    Z Rheumatol; 2024 Feb; 83(Suppl 1):88-96. PubMed ID: 35142908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the efficacy and safety of tofacitinib and peficitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Song GG
    Int J Rheum Dis; 2020 Jul; 23(7):868-875. PubMed ID: 32483919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.
    Dowty ME; Lin TH; Jesson MI; Hegen M; Martin DA; Katkade V; Menon S; Telliez JB
    Pharmacol Res Perspect; 2019 Dec; 7(6):e00537. PubMed ID: 31832202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis.
    Lee YH; Song GG
    Pharmacology; 2023; 108(6):589-598. PubMed ID: 37591216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
    Olivera PA; Lasa JS; Bonovas S; Danese S; Peyrin-Biroulet L
    Gastroenterology; 2020 May; 158(6):1554-1573.e12. PubMed ID: 31926171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.